Cart
sales@molnova.com
Olmutinib (b)
CAS No. 1353550-13-6
Olmutinib (b)( HM-61713 | BI-1482694 )
Catalog No. M11438 CAS No. 1353550-13-6
Olmutinib (HM61713, BI-1482694) is a pontent and T790M-specific third-generation EGFR inhibitor for treatment of NSCLC.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 51 | In Stock |
|
| 2MG | 31 | In Stock |
|
| 5MG | 49 | In Stock |
|
| 10MG | 77 | In Stock |
|
| 25MG | 132 | In Stock |
|
| 50MG | 176 | In Stock |
|
| 100MG | 276 | In Stock |
|
| 200MG | 452 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameOlmutinib (b)
-
NoteResearch use only, not for human use.
-
Brief DescriptionOlmutinib (HM61713, BI-1482694) is a pontent and T790M-specific third-generation EGFR inhibitor for treatment of NSCLC.
-
DescriptionOlmutinib (HM61713, BI-1482694) is a pontent and T790M-specific third-generation EGFR inhibitor for treatment of NSCLC.Lung Cancer Phase 2 Clinical(In Vitro):Olmutinib potently inhibits EGFR in HCC827 cells expressing EGFRDEL19 (IC50=9.2 nM) and H1975 cells expressing EGFRL858R/T790M (IC50=10 nM). In contrast, the IC50 of olmutinib against cells expressing EGFRWT is 2225 nM.
-
In VitroOlmutinib potently inhibits EGFR in HCC827 cells expressing EGFRDEL19 (IC50=9.2 nM) and H1975 cells expressing EGFRL858R/T790M (IC50=10 nM). In contrast, the IC50 of olmutinib against cells expressing EGFRWT is 2225 nM.
-
In Vivo——
-
SynonymsHM-61713 | BI-1482694
-
PathwayAngiogenesis
-
TargetEGFR
-
RecptorEGFR(cell:H1975)|EGFR(cell:HCC827)
-
Research AreaCancer
-
IndicationLung Cancer
Chemical Information
-
CAS Number1353550-13-6
-
Formula Weight486.5887
-
Molecular FormulaC26H26N6O2S
-
Purity>98% (HPLC)
-
SolubilityDMSO: ≥ 44 mg/mL
-
SMILESCN1CCN(CC1)C2=CC=C(C=C2)NC3=NC4=C(C(=N3)OC5=CC=CC(=C5)NC(=O)C=C)SC=C4
-
Chemical Name2-Propenamide, N-[3-[[2-[[4-(4-methyl-1-piperazinyl)phenyl]amino]thieno[3,2-d]pyrimidin-4-yl]oxy]phenyl]-
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Song HN, et al. J Thorac Oncol. 2016 Apr;11(4):e45-7.
2. Patel H, et al. Eur J Med Chem. 2017 May 11. pii: S0223-5234(17)30388-4.
molnova catalog
related products
-
Theliatinib
Theliatinib a potent and highly selective EGFR inhibitor with anti-tumor activity. Ki of 0.05 nM for wild type EGFR and IC50s of 3 and 22 nM for EGFR and EGFR T790M/L858R mutant respectively.
-
GSK-LSD1 dihydrochlo...
GSK-LSD1 2HCl is a specificity irreversible LSD1 inhibitor (IC50: 16 nM). The selectivity of GSK-LSD1 for LSD1 is >1000 fold over other closely related FAD utilizing enzymes (i.e. MAO-A, LSD2, MAO-B).
-
EGFR-IN-8
EGFR-IN-8 can be a promising candidate for further development to target EGFR TKI-resistant NSCLC. EGFR-IN-8 is a dual EGFR and c-Met inhibitor.
